Suraksha Diagnostic Ltd (SURAKSHA) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Suraksha Diagnostics achieved a significant milestone with the acquisition of a 63% stake in Fetomat Wellness Private Limited, marking its entry into genomic medicine.
- The company expanded its operational footprint by adding eight new centers during the quarter, reaching a total of 58 centers by the end of June 2025.
- Suraksha launched Suraksha Genomics, a dedicated vertical offering advanced genetic and molecular testing services, establishing the first complete genomic laboratory facility in Eastern India.
- The company aims to scale fetal medicine capabilities across 15 to 18 centers in FY26 and expand these services to remote areas in the next two to three years.
- Suraksha Diagnostics invested INR 22 crores to establish the state-of-the-art genomics lab.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.